NCT03267290 is a NA clinical trial of Sonazoid- CEUS, CEMRI, CECT in Hepatocellular Carcinoma (HCC), sponsored by National Taiwan University Hospital.

Who is sponsoring NCT03267290?

NCT03267290 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT03267290?

Interventions in NCT03267290: Sonazoid- CEUS, CEMRI, CECT.

What condition does NCT03267290 study?

NCT03267290 studies Hepatocellular Carcinoma (HCC).

Is NCT03267290 still recruiting?

NCT03267290 is currently completed. Last updated 1 July 2020.

Last reviewed 2020-07-01 · How we verify

NCT03267290

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI

Completed NA Last updated 1 July 2020

What this trial tests

NA trial testing Sonazoid- CEUS, CEMRI, CECT in Hepatocellular Carcinoma (HCC) in 12 participants. Completed in 11 January 2019.

Timeline

1 July 2017

Primary endpoint
29 November 2018

11 January 2019

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	12
Start date	1 July 2017
Primary completion	29 November 2018
Estimated completion	11 January 2019
Sites	1 location across Taiwan

Drugs / interventions tested

Sonazoid- CEUS, CEMRI, CECT

Conditions studied

Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 70, any sex, with Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hepatocellular carcinoma (HCC) is unique regarding diagnosis because the clinical diagnosis without pathology proof is accepted. The dynamic image, including contrast-enhanced computed tomography (CECT) and contrast-enhanced magnetic resonance image (CEMRI) were recognized in many guidelines for diagnosing the HCC. In contrast to the CT and MRI, ultrasound (US) with/without contrast is suggested by several societies as the sufficient surveillance modality. The contrast-enhanced ultrasound (CEUS) has aroused more attentions regarding the rapid improvement of contrast medium. In this study, the investigators conducted a prospective, single-center, open-label trial to compare the efficacy and safety of CEUS + CEMRI in characterizing HCC, in comparison with CECT + CEMRI.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A Prospective Assessment of the Diagnostic Value of Contrast-Enhanced Ultrasound, Dynamic Computed Tomography and Magnetic Resonance Imaging for Patients with Small Liver Tumors.
Hsiao CY, Chen PD, Huang KW. · · 2019 · cited 19× · PMID 31480576 · DOI 10.3390/jcm8091353
DNA Methylation Biomarkers as Prediction Tools for Therapeutic Response and Prognosis in Intermediate-Stage Hepatocellular Carcinoma.
Lu CY, Hsiao CY, Peng PJ, Huang SC, et al · · 2023 · cited 4× · PMID 37760434 · DOI 10.3390/cancers15184465
Plasma Cell-Free Adenomatous Polyposis Coli Gene Promoter Methylation as a Prognostic Biomarker for Hepatocellular Carcinoma.
Hsiao CY, Lu CY, Su HJ, Huang KW. · · 2024 · cited 1× · PMID 38527449 · DOI 10.1159/000538455

Verify or expand the search:

Other recruiting trials for Hepatocellular Carcinoma (HCC)

Currently open trials in the same condition.

NCT07070076 — A Two-Arm, Multicenter, Non-Randomized Controlled Study on the Efficacy of Yttrium-90 (Selective Internal Radiation Ther · NA · recruiting
NCT07476651 — Scout Dose of Resin Microspheres · NA · recruiting
NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
NCT07490262 — A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular · Phase 2, PHASE3 · recruiting
NCT07291076 — A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit · Phase 1, PHASE2 · recruiting

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03267290 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 1 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03267290.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing